Citations

Clear

477 citation(s) found for "Wallace, AM".

Multitarget Stool DNA Screening in Clinical Practice: High Positive Predictive Value for Colorectal Neoplasia Regardless of Exposure to Previous Colonoscopy
Eckmann, Jason D. , Bering, Jamie , Rodríguez, Eduardo A. , Devens, Mary E., Lowrie, Kari L., Then, Sara S., Burger, Kelli N. , Prichard, David O. , Wallace, Michael B. , Gurudu, Suryakanth, Finney, Lila J., Ahlquist, David A. , Kahn, Allon , Rodriguez, Eduardo, Doering, Karen, Then, Sara, Mahoney, Douglas W. , Gurudu, Suryakanth R, Limburg, Paul, Berger, Barry, Wallace, Michael B , Ebner, Derek W. , Doering, Karen A. , Limburg, Paul J. , Berger, Barry M. , Kisiel, John B.

Mayo Clinic

American Journal of Gastroenterology | February 17, 2020 | Volume: 115 | Issue: 4 | Pages: 608-615

10.14309/ajg.0000000000000546 | PMID 32068535 Get It

OBJECTIVES: Multitarget stool DNA (MT-sDNA) testing has grown as a noninvasive screening modality for colorectal cancer (CRC), but real-world clinical data are limited in the post-FDA approval setting. The effect of previous colonoscopy on MT-sDNA performance is not known. We aimed to evaluate findings of colorectal neoplasia (CRN) at diagnostic colonoscopy in patients with positive MT-sDNA testing, stratified by patient exposure to previous colonoscopy. METHODS: We identified consecutive patients completing MT-sDNA testing over a 39-month period and reviewed the records of those with positive tests for neoplastic findings at diagnostic colonoscopy. MT-sDNA test positivity rate, adherence to diagnostic colonoscopy, and the positive predictive value (PPV) of MT-sDNA for any CRN and neoplastic subtypes were calculated. RESULTS: Of 16,469 MT-sDNA tests completed, testing returned positive in 2,326 (14.1%) patients. After exclusion of patients at increased risk for CRC, 1,801 patients remained, 1,558 (87%) of whom underwent diagnostic colonoscopy; 918 of 1,558 (59%) of these patients had undergone previous colonoscopy, whereas 640 (41%) had not. Any CRN was found in 1,046 of 1,558 patients (PPV = 67%). More neoplastic lesions were found in patients without previous colonoscopy (73%); however, the rates remained high among those who had undergone previous colonoscopy (63%, P < 0.0001). The large majority (79%) of patients had right-sided neoplasia. DISCUSSION: MT-sDNA has a high PPV for any CRN regardless of exposure to previous colonoscopy. Right-sided CRN was found at colonoscopy in most patients with positive MT-sDNA testing, representing a potential advantage over other currently available screening modalities for CRC.
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial
Chien, A. Jo , Tripathy, Debasish , Albain, Kathy S. , Symmans, W. Fraser , Melisko, Michelle , Schwab, Richard B. , Forero‐Torres, Andres , Stringer-Reasor, Erica , Ellis, Erin D. , Nanda, Rita , Jaskowiak, Nora , Godellas, Constantine , Haley, Barbara , Kemmer, Kathleen, Clark, Amy S. , Lang, Julie E. , Lu, Janice , Korde, Larissa A. , Edmiston, Kirsten K., Northfelt, Donald W. , Viscusi, Rebecca K., Yee, Douglas , Perlmutter, Jane , Veer, Laura J. van’t , Wilson, Amy , Peterson, Garry , Buxton, Meredith , Paoloni, Melissa, Clennell, Julia L. , Matthews, Jeffrey B. , Steeg, Katherine, Singhrao, Ruby , Hirst, Gillian L. , Sanil, Ashish, Asare, Smita , Berry, Donald A. , Esserman, Laura J. , Symmans, W Fraser , Esserman, Laura J , Hirst, Gillian L , Yee, Douglas , Rugo, Hope S. , Wallace, Anne M. , Helsten, Teresa L. , Kaplan, Henry G. , Murthy, Rashmi Krishna , Boughey, Judy C. , Elias, Anthony , Isaacs, Claudine , Hylton, Nola M. , DeMichele, Angela , Berry, Scott , Matthews, Jeffrey B., Yau, Christina

Mayo Clinic

Journal of Clinical Oncology | February 7, 2020 | Volume: 38 | Issue: 10 | Pages: 1059-1069

10.1200/jco.19.01027 | PMID 32031889 Get It

PURPOSEThe phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survival and therapeutic resistance in breast cancer. We evaluated the pan-Akt inhibitor MK-2206 in combination with standard therapy in patients with high-risk early-stage breast cancer.PATIENTS AND METHODSI-SPY 2 is a multicenter, phase II, open-label, adaptively randomized neoadjuvant platform trial that screens experimental therapies and efficiently identifies potential predictive biomarker signatures. Patients are categorized by human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), and MammaPrint statuses in a 2 × 2 × 2 layout. Patients within each of these 8 biomarker subtypes are adaptively randomly assigned to one of several experimental therapies, including MK-2206, or control. Therapies are evaluated for 10 biomarker signatures, each of which is a combination of these subtypes. The primary end point is pathologic complete response (pCR). A therapy graduates with one or more of these signatures if and when it has an 85% Bayesian predictive probability of success in a hypothetical phase III trial, adjusting for biomarker covariates. Patients in the current report received standard taxane- and anthracycline-based neoadjuvant therapy without (control) or with oral MK-2206 135 mg/week.RESULTSMK-2206 graduated with 94 patients and 57 concurrently randomly assigned controls in 3 graduation signatures: HR-negative/HER2-positive, HR-negative, and HER2-positive. Respective Bayesian mean covariate-adjusted pCR rates and percentage probability that MK-2206 is superior to control were 0.48:0.29 (97%), 0.62:0.36 (99%), and 0.46:0.26 (94%). In exploratory analyses, MK-2206 evinced a numerical improvement in event-free survival in its graduating signatures. The most significant grade 3-4 toxicity was rash (14% maculopapular, 8.6% acneiform).CONCLUSIONThe Akt inhibitor MK-2206 combined with standard neoadjuvant therapy resulted in higher estimated pCR rates in HR-negative and HER2-positive breast cancer. Although MK-2206 is not being further developed at this time, this class of agents remains of clinical interest.
Early detection and imaging strategies to reveal and target developing pancreatic cancer
Wallace, Michael B. , Störz, Peter , Wallace, Michael B , Crawford, Howard C.

Mayo Clinic

Expert Review of Anticancer Therapy | January 27, 2020 | Volume: 20 | Issue: 2 | Pages: 81-83

10.1080/14737140.2020.1720654 | PMID 31986932 Get It

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., Dilling, Thomas J. , Dobelbower, M.C., Gettinger, Scott , Govindan, Ramaswamy , Gubens, Matthew A. , Hennon, Mark, Horn, Leora , Lackner, Rudy P., Leal, Ticiana , Lin, Jules , Loo, Billy W. , Martins, Renato , Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Shapiro, Theresa A. , Stevenson, James, Swanson, Scott J. , Tauer, Kurt W., Yang, Stephen C. , Gregory, Kristina M., OCN, Hughes, Miranda, Schild, Steven E. , Loo, Billy W , Govindan, Ramaswamy , Aggarwal, Charu , Bharat, Ankit , Chang, Joe Y. , Lanuti, Michael D. , Reckamp, Karen L. , OCN, Hughes, Miranda

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 5, 2019 | Volume: 17 | Issue: 12 | Pages: 1464-1472

10.6004/jnccn.2019.0059 | PMID 31805526 Get It

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as “preferred interventions,” whereas others are categorized as either “other recommended interventions” or “useful under certain circumstances.”
International consensus statements for endoscopic management of distal biliary stricture
Nakai, Yousuke , Rerknimitr, Rungsun , Khor, Christopher , Yasuda, Ichiro , Lau, James Y. , Lakhtakia, Sundeep , Ratanachu‐ek, Thawee , Lee, Dong Ki , Makmun, Dadang , Dy, Frederick, Draganov, Peter V. , Almadi, Majid A. , Ryozawa, Shomei , Wallace, Michael B. , Itoi, Takao , Devereaux, Benedict , Aniwan, Satimai , Makmun, Dadang , Rerknimitr, Rungsun , Yasuda, Ichiro , Lau, James , Lakhtakia, Sundeep , Kitano, Masayuki , Devereaux, Benedict , Wallace, Michael B , Isayama, Hiroyuki , Wang, Hsiu‐Po , Kogure, Hirofumi , Moon, Jong Ho , Seo, Dong Wan , Liao, Wei‐Chih , Irisawa, Atsushi , Katanuma, Akio , Fujisawa, Toshio

Mayo Clinic

Journal of Gastroenterology and Hepatology | December 5, 2019 | Volume: 35 | Issue: 6 | Pages: 967-979

10.1111/jgh.14955 | PMID 31802537 Get It

AbstractDistal biliary strictures (DBS) are common and may be caused by both malignant and benign pathologies. While endoscopic procedures play a major role in their management, a comprehensive review of the subject is still lacking. Our consensus statements were formulated by a group of expert Asian pancreatico‐biliary interventional endoscopists, following a proposal from the Digestive Endoscopy Society of Taiwan, the Thai Association for Gastrointestinal Endoscopy, and the Tokyo Conference of Asian Pancreato‐biliary Interventional Endoscopy. Based on a literature review utilizing Medline, Cochrane library, and Embase databases, a total of 19 consensus statements on DBS were made on diagnosis, endoscopic drainage, benign biliary stricture, malignant biliary stricture, and management of recurrent biliary obstruction and other complications. Our consensus statements provide comprehensive guidance for the endoscopic management of DBS.
The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4‐Related Disease
Wallace, Zachary S. , Naden, Ray, Chari, Suresh T. , Choi, Hyon K. , Della‐Torre, Emanuel, Dicaire, Jean‐Francois, Hart, Phil A. , Inoue, Dai , Khosroshahi, Arezou , Lanzillotta, Marco , Okazaki, Kazuichi , Perugino, Cory A. , Saeki, Takako , Sekiguchi, Hiroshi , Schleinitz, N. , Stone, James R. , Takahashi, Naoki , Umehara, Hisanori , Webster, George, Zen, Yoh , Stone, John H. , Culver, Emma , Frulloni, Luca , Lerch, Markus M. , Matsui, Shoko , Rosenbaum, James T. , Chari, Suresh, Choi, Hyon , Stone, John H , Takahashi, Naoki , Chari, Suresh T , Della‐Torre, Emanuel , Kawano, Mitsuhiro , Kubota, Kensuke , Sharma, Amita , Fernández‐Codina, Andreu

Mayo Clinic

Arthritis & Rheumatology | December 3, 2019 | Volume: 72 | Issue: 1 | Pages: 7-19

10.1002/art.41120 | PMID 31793250 Get It

Objective IgG4‐related disease (IgG4‐ RD ) can cause fibroinflammatory lesions in nearly any organ. Correlation among clinical, serologic, radiologic, and pathologic data is required for diagnosis. This work was undertaken to develop and validate an international set of classification criteria for IgG4‐ RD . Methods An international multispecialty group of 86 physicians was assembled by the American College of Rheumatology ( ACR ) and the European League Against Rheumatism ( EULAR ). Investigators used consensus exercises, existing literature, derivation and validation cohorts of 1,879 subjects (1,086 cases, 793 mimickers), and multicriterion decision analysis to identify, weight, and test potential classification criteria. Two independent validation cohorts were included. Results A 3‐step classification process was developed. First, it must be demonstrated that a potential IgG4‐ RD case has involvement of at least 1 of 11 possible organs in a manner consistent with IgG4‐ RD . Second, exclusion criteria consisting of a total of 32 clinical, serologic, radiologic, and pathologic items must be applied; the presence of any of these criteria eliminates the patient from IgG4‐ RD classification. Third, 8 weighted inclusion criteria domains, addressing clinical findings, serologic results, radiology assessments, and pathology interpretations, are applied. In the first validation cohort, a threshold of 20 points had a specificity of 99.2% (95% confidence interval [95% CI ] 97.2–99.8%) and a sensitivity of 85.5% (95% CI 81.9–88.5%). In the second, the specificity was 97.8% (95% CI 93.7–99.2%) and the sensitivity was 82.0% (95% CI 77.0–86.1%). The criteria were shown to have robust test characteristics over a wide range of thresholds. Conclusion ACR / EULAR classification criteria for IgG4‐ RD have been developed and validated in a large cohort of patients. These criteria demonstrate excellent test performance and should contribute substantially to future clinical, epidemiologic, and basic science investigations.
Trends and factors affecting the US adult hematology workforce: a mixed methods study
Sharma, Deva , Wallace, Natalie , Levinsohn, Erik A. , Marshall, Ariela L. , Kayoumi, Karen M., Madero, Johanna, Homer, Morgan, Reynolds, Robby , Hafler, Janet P. , Podoltsev, Nikolai A. , Lee, Alfred Ian , Marshall, Ariela , Podoltsev, Nikolai , Wallace, Natalie, Reynolds, Robby

Mayo Clinic

Blood Advances | November 20, 2019 | Volume: 3 | Issue: 22 | Pages: 3550-3561

10.1182/bloodadvances.2019000307 | PMID 31738829 Get It

Key Points A mixed methods study of surveys, interviews, and focus groups raises concerns about the state of the adult hematology workforce. Hematology/oncology fellowship program directors, fellows, and practicing clinicians offer different strategies to address these problems.
Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity
Crouch, Eric R. , Kraker, Raymond T. , Wallace, David K. , Holmes, Jonathan M. , Repka, Michael X. , Collinge, Janine E., Bremer, Don L., Gray, Michael E. , Smith, Heather , Steinkuller, Paul G., Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | November 7, 2019 | Volume: 138 | Issue: 1 | Pages: 14

10.1001/jamaophthalmol.2019.4488 | PMID 31697304 Get It

New artificial intelligence system: first validation study versus experienced endoscopists for colorectal polyp detection
Hassan, Cesare , Wallace, Michael B. , Maselli, Roberta , Craviotto, Vincenzo , Spadaccini, Marco , Repici, Alessandro , Spadaccini, Marco , Hassan, Cesare , Wallace, Michael B , Sharma, Prateek

Mayo Clinic

Gut | October 15, 2019 | Volume: 69 | Issue: 5 | Pages: 799-800

10.1136/gutjnl-2019-319914 | PMID 31615835 Get It